PATENT CLAIM ANALYSIS

Application Number: 15981103
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "011700"]

Abstract:
Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Claim (Index 20):
The method of  claim 19 , wherein the [Gly2]hGLP-2 is administered over a period of at least 21 days.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 93.0
- Lexical Diversity: 1.04348
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15286457', '15285729', '15285743', '15285855', '15285852']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8105262637767666
- 35 USC 102 Novelty (BERT): 0.572619142375223
- Combined Prediction Score: 0.7867355516366124
- Mean Citation Score: 459.862858
- Max Citation Score: 460.50934000000007
- Similarity Product: 375.2202215526796

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test